Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8072956 | 0.76 | TRPV4 (0.58) | TRPV4 | |
| SCHEMBL25921514 | 0.76 | LOXL2 (0.31) | — | |
| SCHEMBL146646 | 0.75 | CCR1 (0.52) | TRPV4 | |
| SCHEMBL14327688 | 0.75 | KIF11 (0.38) | TRPV4 | |
| SCHEMBL701703 | 0.73 | TSHR (0.46) | — | |
| SCHEMBL2367892 | 0.71 | KDM4E (0.46) | TRPV4 | |
| SCHEMBL15122279 | 0.71 | TRPV4 (0.32) | TRPV4 | |
| SCHEMBL20782529 | 0.71 | TRPV4 (0.37) | TRPV4 | |
| SCHEMBL1474089 | 0.71 | LMNA (0.42) | — | |
| SCHEMBL2609326 | 0.71 | CCR9 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036219-B2 | Methods of treating infections in overweight and obese patients using antibiotics | MELINTA SUBSIDIARY CORP. (US) | 2024-07-16 | — | — | US | disclosed |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | MELINTA SUBSIDARY CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10428076-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC | 2017-06-22 | — | — | US | disclosed |
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9409896-B2 | Sustained release pharmaceutical compositions comprising an antibacterial agent | MELINTA THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160136137-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | MELINTA SUBSIDIARY CORP. | 2016-05-19 | — | — | US | disclosed |
| US-20160058750-A1 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS | MELINTA SUBSIDIARY CORP. | 2016-03-03 | — | — | US | disclosed |
| EP-2714704-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2015-04-29 | — | — | EP | disclosed |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | RIB-X PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7705026-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7456206-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070197541-A1 | Biaryl heterocyclic amines,amides, and sulfur-containing compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058750-A1 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS | NCEH1, NRDC, LPL | TRPV4 4829/4885 |
| US-12036219-B2 | Methods of treating infections in overweight and obese patients using antibiotics | NCEH1, NRDC, LPL | TRPV4 4829/4885 |
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | TRPV4 4550/4885 |
| US-20170174693-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A1, GUCY1A2, PDE2A | TRPV4 2658/4885 |
| US-10030027-B2 | Soluble guanylate cyclase stimulators | GUCY1A1, GUCY1A2, PDE2A | TRPV4 2658/4885 |
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | PCNA, AADAC, MIF | TRPV4 4550/4885 |
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | TRPV4 4592/4885 |
| US-10428076-B2 | Soluble guanylate cyclase stimulators | GUCY1A1, GUCY1A2, PDE2A | TRPV4 2658/4885 |
| US-20160136137-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | CUTA, CYP17A1, HSD17B11 | TRPV4 1213/4885 |
| US-20070197541-A1 | Biaryl heterocyclic amines,amides, and sulfur-containing compounds and methods of making and using the same | SQOR, AADAC, TST | TRPV4 4753/4885 |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | PCNA, AADAC, MIF | TRPV4 4550/4885 |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | CUTA, CYP17A1, HSD17B11 | TRPV4 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.